Cannabis

What Metric Jim Cramer Watches in Every Cannabis Earnings Report

Overwhelmed by the cannabis earnings reports? Here's the metric that Jim Cramer watches.

Katherine Ross

Mar 20, 2019 6:02 AM EDT

The Fed's March Meeting: 3 Things Stock Investors Should Look Out For

Plus, why investors should care about the yield curve, and a closer look at Tilray's quarter.

Jacob Sonenshine

Mar 19, 2019 4:17 PM EDT

Pot Stocks Trade Mixed Following Tilray's Fourth-Quarter Results

Tilray shares turn following the company's fourth-quarter results while other pot stocks trade mixed.

Tony Owusu

Mar 19, 2019 1:56 PM EDT

Cause for Caution? Top Executives Selling Tilray Stock

It might not be time to panic yet about Tilray, but there's likely a problem ahead.

Kevin Curran

Mar 19, 2019 1:48 PM EDT

With Tilray, You Won't Win Any Valuation Arguments

Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.

Timothy Collins

Mar 19, 2019 1:39 PM EDT

Another Hemp Play to Consider: Charlotte's Web Holdings

Investors looking for another hemp play might consider Charlotte's Web Holdings, which deals in a range of CBD wellness products.

Bruce Kamich

Mar 19, 2019 1:15 PM EDT

How Jim Cramer Felt About Tilray's Earnings Call

Jim Cramer says that Tilray's earnings call disappointed him. Here's why he wasn't blown away.

Katherine Ross

Mar 19, 2019 11:23 AM EDT

Tilray Touts Global Ambition as Erosion of Canadian Market Expected

A key aspect of the international expansion is the company's recent acquisition of hemp-food producer Manitoba Harvest in February.

Kevin Curran

Mar 19, 2019 11:07 AM EDT

Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk

Bristol-Myers, Tilray, and Elon Musk are some of the top headlines in business news Tuesday. Here's what Jim Cramer's watching.

Katherine Ross

Mar 19, 2019 10:48 AM EDT

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.

Doug Kass

Mar 19, 2019 10:30 AM EDT

The Future of Cannabis: Edibles & Oil Based Products

Marijuana Co. of America Buys Distributor as California's Pot Market Grows

Why Jim Cramer Believes Canopy Could Be the Next Amazon

Trading Tilray Stock's Wild Post-Earnings Volatility

Tilray Is Not My Favorite Canadian Cannabis Stock

Curaleaf to Acquire Nevada-Based Acres Cannabis for $70 Million

Hexo Lights Up on Narrower Quarterly Loss

Aurora Is an 'Undervalued Company,' Says Jim Cramer

Aurora Cannabis Spikes After Billionaire Activist Nelson Peltz Added as Adviser

HEXO Boosts Production Capacity With Newstrike Brands Acquisition

Cannabis Is a Safe Haven If Economy Slows Down

Pyxus International: Here's a Way to Trade the Cannabis Stock

Cronos Is Too Expensive at Current Levels, BMO Report Says

Tilray's Valuation Worries Jefferies in Bearish Initiation

Here's Why Aurora Cannabis Is Now Cowen's Top Cannabis Stock

Cronos Sells Stake in Whistler Medical Marijuana to Aurora Cannabis

Smart Money Sees Green in Cannabis Oil and Edibles

Jim Cramer's Reaction to Canopy Growth's Partnership with Martha Stewart

Canopy Growth Taps Martha Stewart to Advise on CBD Products

Jefferies Analyst Rates Aurora Cannabis and 4 Other Pot Stocks as Buys

Canopy Growth Declines After Adjusting Third-Quarter Results

Primer For Overlooked Canadian Pot Stocks

Tilray Scoops Up Hemp-Food Maker Manitoba Harvest

Investing Ideas for Extraction and Vape

Canopy Rises on Q3 Revenue Beat but Here's Why You Should Watch Out for Margins

Aurora Cannabis Posts Big Revenue Surge but Swings to a Loss

Aphria Tumbles After Rejecting Hostile Takeover Bid From Green Growth Brands

Pot Stocks Fade as Momentum Cools

Canopy Growth Shares Jump as Analyst Lifts Price Target

Excuse Me, Would You Like Some Cannabis With Your Coffee?

What Metric Jim Cramer Watches in Every Cannabis Earnings Report

The Fed's March Meeting: 3 Things Stock Investors Should Look Out For

Pot Stocks Trade Mixed Following Tilray's Fourth-Quarter Results

Cause for Caution? Top Executives Selling Tilray Stock

With Tilray, You Won't Win Any Valuation Arguments

Another Hemp Play to Consider: Charlotte's Web Holdings

How Jim Cramer Felt About Tilray's Earnings Call

Tilray Touts Global Ambition as Erosion of Canadian Market Expected

Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Watchlist

What stocks are you watching?

What stocks are you watching?

This account is currently pending confirmation.

Advertising Partners